AbbVie Exceeds Q4 2025 Expectations, Forecasts Strong 2026 Profit on Immunology Drug Sales
Feb 4, 2026
AbbVie reported fourth-quarter 2025 sales of $16.62 billion, beating analyst expectations. The company posted full-year net revenues of $61.16 billion, an increase of 8.6% from the previous year. This growth was driven by strong demand for newer immunology medicines, Skyrizi and Rinvoq.
Sales of Skyrizi reached $17.56 billion worldwide in 2025, while Rinvoq generated $8.30 billion in global revenue. Together, these drugs offset a smaller-than-expected decline in sales of Humira, AbbVie's older inflammation treatment, which totaled $4.54 billion globally for the year.
AbbVie’s total immunology portfolio generated $30.41 billion in revenue in 2025, marking an increase of 14%. The company also saw growth in its neuroscience business but faced declines in its oncology and aesthetics portfolios.
Looking ahead, AbbVie forecasted 2026 adjusted earnings per share above Wall Street estimates, pointing to continued strong performance for Skyrizi and Rinvoq.
What are Skyrizi and Rinvoq?
Skyrizi and Rinvoq are medicines developed by AbbVie to treat immune system-related conditions, such as arthritis and Crohn's disease.
Why is Humira's decline important?
Humira was previously AbbVie's top-selling drug. Its sales have been falling due to competition, so newer drugs like Skyrizi and Rinvoq are helping to make up the difference.
How did AbbVie's profits and sales compare to last year?
AbbVie increased its annual revenues by 8.6% in 2025 compared to the previous year, thanks to growth in its immunology portfolio.
What challenges does AbbVie face going forward?
AbbVie continues to rely heavily on its immunology drugs for growth, while other areas like oncology and aesthetics have declined. There are concerns about how the company will grow in the future if these challenges continue.
Sources
AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology...
Reuters
Reuters
AbbVie forecast 2026 profit above Wall Street estimates on Wednesday after posting a fourth-quarter results beat, fueled by strong demand for newer immunology drugs Skyrizi and Rinvoq and a smaller-than-expected decline in sales of its older medicine Humira.
AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results
Reports Full-Year Diluted EPS of $2.36 on a GAAP Basis, a Decrease of 1.3 Percent; Adjusted Diluted EPS of $10.00, a Decrease of 1.2 Percent; These Results Include an Unfavorable Impact of $2.76 Per Share Related to 2025 Acquired IPR&D and Milestones Expense Delivers Full-Year Net Revenues of $61...
AbbVie Revenue Rises on Immunology Growth
WSJ
WSJ
AbbVie posted higher fourth-quarter revenue on the back of growth from its immunology portfolio, led by arthritis and Crohn's disease drugs Skyrizi and Rinvoq.
AbbVie's Inflammation Drug Humira Slows, But Skyrizi, Rinvoq Drive Revenue Growt...
Benzinga
Benzinga
AbbVie Inc. (NYSE: ABBV) reported fourth-quarter 2025 sales of $16.62 billion on Wednesday, beating the consensus of $16.42 billion.
AbbVie's Immunology Fortress Can't Hide Cracks In Diversification (Downgrade)
Seeking Alpha
Seeking Alpha
AbbVie Inc. faces investor skepticism on growth durability beyond Immunology, despite strong SKYRIZI and RINVOQ performance offsetting HUMIRA's decline. ABBV's Q4 2025 saw 18% Immunology growth and 10% total revenue growth, but Oncology and Aesthetics portfolios declined, highlighting diversificatio...
AbbVie Q4 Earnings Review: I May Have Just Made A Huge Mistake
Seeking Alpha
Seeking Alpha
AbbVie Inc. has delivered strong long-term returns and maintains a >3% dividend yield, but recent Q4 earnings and guidance have tempered my near-term enthusiasm. ABBV's immunology and neuroscience divisions are thriving, with Skyrizi and Rinvoq driving robust growth, yet competition and market satur...
AbbVie: Double-Digit Growth For Immunology Products Continues With HUMIRA Surpri...
Seeking Alpha
Seeking Alpha
AbbVie Inc. retains a Strong Buy rating, driven by a positive earnings surprise in Q4 2025, notably due to HUMIRA outperformance. Despite ongoing HUMIRA declines, ABBV demonstrates robust growth in its immunology and neuroscience portfolios, supporting continued optimism. The company's ability to ex...
AbbVie: Skyrizi And Rinvoq Growth Isn't Everything, But It's A Lot
Seeking Alpha
Seeking Alpha
AbbVie has significantly outperformed prior immunology sales projections, with Skyrizi and Rinvoq now expected to reach $38 billion by 2030. ABBV's oncology and neuroscience pipelines have expanded via ImmunoGen and Cerevel acquisitions, supporting robust growth beyond immunology. Sales and EPS grow...
AbbVie: The Market Is Getting It Wrong
Seeking Alpha
Seeking Alpha
AbbVie delivered a resilient Q4 with 10% YoY revenue growth and strong immunology performance, despite a post-earnings stock selloff. Their adjusted EPS grew 25% YoY, beating estimates, while operating margin expanded 360 bps, demonstrating improved efficiency. Forward guidance for FY2026 EPS of $14...
IQVIA Q4 Earnings & Revenues Beat Estimates, Increase Y/Y
Zacks Investment Research
Zacks Investment Research
IQV posted a fourth-quarter 2025 earnings and revenue beat with double-digit Y/Y sales growth, strong segment gains and upbeat 2026 revenue guidance.
Related Posts
Other News
Corporate Moves
View All
Kraft Heinz Pauses Company Split to Focus on Business Improvements
8 hours ago
KHC
+0.4%
Kraft Heinz has announced its financial results for the fourth quarter and full year 2025. Alongside the results, the company said it will pause its plans to split the company into separate businesses...
Heineken to Cut Up to 6,000 Jobs as Beer Demand Drops
8 hours ago
HEIA
+4.29%
HEIO
+3.79%
Heineken, the Dutch brewing company, announced it will cut between 5,000 and 6,000 jobs from its global workforce over the next two years. This decision comes as demand for beer has weakened and the c...
Kyndryl Delays Quarterly Report, CFO Departs Amid Accounting Concerns
Feb 9, 2026
KD
+8.27%
Kyndryl, an IT services company spun off from IBM, has delayed the filing of its latest quarterly financial report. The company said it expects to find significant weaknesses in how it manages and rep...
Product Launches
View All
Hims & Hers Health Launches $49 Compounded Wegovy Pill Alternative
Feb 5, 2026
HIMS
-3.25%
Hims & Hers Health, an online telehealth company, has announced that it will start offering a compounded version of the popular Wegovy weight loss pill for $49 per month. This price is about $100 less...
Amazon Expands AI Integration with Alexa+ Launch and Media Production Tools
Feb 4, 2026
AMZN
-1.23%
Amazon has made its AI-powered digital assistant, Alexa+, available to all users in the United States. Previously, Alexa+ was in an early access phase, requiring consumers to join a waitlist or purcha...
Tesla Launches Robotaxi Rides Without Human Safety Drivers in Austin, Stock Rises
Jan 22, 2026
TSLA
+0.44%
Tesla has started offering robotaxi rides in Austin, Texas, without a human safety driver or monitor in the car. This marks a new milestone in the company's efforts to develop self-driving vehicles. P...
Regulatory Actions
View All
FDA Refuses to Review Moderna's Flu Vaccine Application
22 hours ago
MRNA
-3.26%
Moderna announced that the U.S. Food and Drug Administration (FDA) has refused to review its application for an experimental flu shot, known as mRNA-1010. The FDA issued a Refusal-to-File (RTF) letter...
EU Moves Against Meta Over Blocking Rival AI Assistants on WhatsApp
Feb 9, 2026
META
-0.05%
The European Union (EU) has charged Meta Platforms, the owner of WhatsApp, with breaking antitrust rules by blocking rival artificial intelligence (AI) assistants from its messaging app WhatsApp.
The...
Hims & Hers Stops Selling Compounded Weight-Loss Pill After FDA Warning
Feb 8, 2026
HIMS
-3.25%
Hims & Hers has decided to stop offering its compounded semaglutide weight-loss pill. This decision came after the U.S. Food and Drug Administration (FDA) said it would take action against the company...
Earnings
View All
Zillow Posts Profit in Q4 2025 with Strong Revenue Growth
6 hours ago
ZG
-18.53%
Zillow Group reported a profit of $3 million for the fourth quarter of 2025, compared to a loss of $52 million in the same period last year. Fourth-quarter revenue reached $654 million, representing a...
Mattel Shares Plunge After Missing Earnings Expectations and Issuing Weak Forecast
7 hours ago
MAT
-25.5%
Mattel, the maker of Barbie, reported fourth-quarter financial results that missed Wall Street estimates for both sales and profit. Despite a 7% increase in net sales to $1.77 billion during the quart...
Gilead Sciences Reports Strong Q4 2025 Results, Sets Modest Outlook for 2026
7 hours ago
GILD
+6.17%
Gilead Sciences announced its financial results for the fourth quarter and full year of 2025. The company reported earnings and sales that were slightly above Wall Street estimates for the quarter.
G...
Stock Movements
View All
Bill Ackman's Pershing Square Invests $2 Billion in Meta Platforms
1 hour ago
META
-0.05%
Billionaire investor Bill Ackman's hedge fund, Pershing Square, has disclosed a large investment in Meta Platforms, the company behind Facebook, Instagram, and WhatsApp.
Pershing Square invested arou...
Astera Labs Shares Drop After Strong Fourth-Quarter Results and Guidance
2 hours ago
ALAB
-21.61%
Astera Labs reported its fourth-quarter earnings, surpassing analyst expectations for both revenue and earnings per share. The company also gave strong guidance for the upcoming quarter, with leadersh...
Unity Software Shares Drop Nearly 30% After Weak Outlook Despite Strong Q4 Results
3 hours ago
U
-24.81%
Unity Software, a company known for its game development platform, reported its financial results for the fourth quarter and full year ending December 31, 2025. The company delivered results that exce...
Economy
View All
U.S. Retail Sales Remain Flat in December, Missing Expectations
Feb 10, 2026
Retail sales in the United States did not grow in December, according to the latest report from the Census Bureau. Sales were unchanged from the previous month, following a 0.6% increase in November....
Private Sector Adds 22,000 Jobs in January, Falling Short of Expectations
Feb 4, 2026
The ADP National Employment Report showed that private sector employment in the United States grew by 22,000 jobs in January 2026. This was lower than many analysts had expected, with forecasts antici...
U.S. and India Announce Trade Deal to Lower Tariffs
Feb 2, 2026
The United States and India have reached a new trade agreement, as announced by President Donald Trump. A key part of the deal is that the U.S. will immediately lower its tariff on Indian goods from 2...
Analyst Ratings
View All
Oracle Stock Rebounds After Analyst Upgrade and AI Concerns Ease
Feb 9, 2026
ORCL
-1.83%
Oracle shares have recently faced a significant decline, dropping over 13% in the past five trading days. The downturn was driven by worries about the company's large investments in artificial intelli...
Microsoft Stock Faces Downgrade Amid Growing AI Competition
Feb 6, 2026
MSFT
-2.29%
Microsoft's stock has recently faced pressure after receiving a downgrade from Stifel, which cited increasing competition in artificial intelligence from companies like Google and Anthropic. The downg...
Super Micro Computer (SMCI) Faces Challenges Despite AI Growth Benefits
Jan 13, 2026
SMCI
-4.08%
Super Micro Computer (SMCI) has gained attention as a key assembler of advanced data center computing infrastructure, benefiting from the ongoing growth in artificial intelligence (AI).
Despite its s...
Mergers & Acquisitions
View All
Paramount Increases Offer for Warner Bros. Discovery with Added Shareholder Benefits
Feb 10, 2026
WBD
+0.59%
PARA
-6.04%
Paramount has revised its $30 per share, all-cash offer for Warner Bros. Discovery (WBD) by adding new incentives for WBD shareholders. The new terms include a $0.25 per share 'ticking fee,' which wil...
Transocean to Acquire Valaris in $5.8 Billion All-Stock Deal
Feb 10, 2026
RIG
+10.11%
VAL
+10.7%
Transocean has agreed to acquire its competitor Valaris in an all-stock transaction valued at approximately $5.8 billion. The combined company will become the world's largest and most advanced offshor...
NatWest Agrees to Buy Evelyn Partners for £2.7 Billion
Feb 9, 2026
NWG
+0.99%
NatWest Group has announced an agreement to acquire Evelyn Partners, one of the UK's largest wealth management firms, in a deal valued at £2.7 billion ($3.7 billion), including debt.
With this acquis...
IPO
View All
Once Upon a Farm, Co-Founded by Jennifer Garner, Raises Nearly $198 Million in IPO
Feb 6, 2026
Once Upon a Farm, an organic children's food company co-founded by actress Jennifer Garner, has successfully gone public in the United States. The company raised nearly $198 million in its initial pub...
Bob's Discount Furniture Raises $330.7 Million in NYSE Debut
Feb 5, 2026
AAAGY
Bob's Discount Furniture has raised $330.7 million through its initial public offering (IPO) in the United States. The company's shares were priced at $17 each. In total, 19,450,000 shares were offere...
EquipmentShare Raises $747 Million in Nasdaq Debut, Valued Over $7 Billion
Jan 23, 2026
EquipmentShare.com Inc, a leading provider of equipment rentals and construction technology, has completed its initial public offering (IPO). The company offered 30,500,000 shares of its Class A commo...
